1. 936PDA phase II study of durvalumab, a PD-L1 inhibitor and olaparib in recurrent ovarian cancer (OvCa). (23rd October 2018) Authors: Lee, J-M; Annunziata, C M; Houston, N; Kohn, E C; Lipkowitz, S; Minasian, L; Nichols, E; Trepel, J; Trewhitt, K; Zia, F; Zimmer, A D S Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. (7th February 2019) Authors: Liu, J F; Barry, W T; Birrer, M; Lee, J -M; Buckanovich, R J; Fleming, G F; Rimel, B J; Buss, M K; Nattam, S R; Hurteau, J; Luo, W; Curtis, J; Whalen, C; Kohn, E C; Ivy, S P; Matulonis, U A Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗